Oncotelic Therapeutics, Inc. SEC filings OTLC

Oncotelic Therapeutics, Inc. has 1,007 filings in SEC EDGAR's recent list, going back to Jul 19, 2005. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 26, 2026 (other events). The company's fiscal year ends on December 31.

Form Description Filed Period
DEF 14A Proxy statement Jun 25, 2020 Jun 25, 2020
PRE 14A Preliminary proxy statement Apr 13, 2020 Apr 13, 2020
PRE 14A Preliminary proxy statement Oct 18, 2019 Oct 18, 2019
PRE 14C Filing May 22, 2019 May 14, 2019
DEFA14A Additional proxy material May 7, 2018 —
DEF 14A Proxy statement May 7, 2018 Jun 20, 2018
PRE 14A Preliminary proxy statement Apr 24, 2018 Jun 20, 2018
DEFA14A Additional proxy material Apr 26, 2017 —
DEF 14A Proxy statement Apr 26, 2017 Jun 9, 2017
DEFA14A Additional proxy material Nov 8, 2016 —
DEFA14A Additional proxy material Oct 4, 2016 —
DEFA14A Additional proxy material Oct 4, 2016 —
DEF 14A Proxy statement Oct 3, 2016 Nov 11, 2016
PRE 14A Preliminary proxy statement Sep 7, 2016 Nov 1, 2016
DEFA14A Additional proxy material May 16, 2016 —
DEF 14A Proxy statement Apr 25, 2016 Jun 1, 2016
PRE 14A Preliminary proxy statement Apr 14, 2016 Jun 1, 2016
DEF 14A Proxy statement Apr 17, 2015 May 28, 2015
PRE 14A Preliminary proxy statement Apr 6, 2015 May 28, 2015
DEF 14A Proxy statement Apr 30, 2014 Jun 10, 2014
DEFA14A Additional proxy material Jul 1, 2013 —
DEFA14A Additional proxy material Jun 27, 2013 —
DEF 14A Proxy statement Jun 13, 2013 Jul 16, 2013
PRE 14A Preliminary proxy statement Jun 3, 2013 Jul 16, 2013
DEFA14A Additional proxy material Nov 19, 2012 —
DEF 14A Proxy statement Nov 19, 2012 Dec 21, 2012
PRE 14A Preliminary proxy statement Nov 9, 2012 Nov 9, 2012
DEFA14A Additional proxy material Nov 8, 2012 —
DEFA14A Additional proxy material Apr 23, 2012 —
DEF 14A Proxy statement Apr 20, 2012 May 24, 2012
PRE 14A Preliminary proxy statement Apr 9, 2012 May 24, 2012
DEFA14A Additional proxy material Oct 18, 2011 —
DEF 14A Proxy statement Sep 22, 2011 Oct 31, 2011
DEF 14A Proxy statement Feb 18, 2011 Mar 18, 2011
PRE 14A Preliminary proxy statement Feb 7, 2011 Feb 7, 2011
DEF 14A Proxy statement Nov 12, 2010 Dec 21, 2010
PRE 14A Preliminary proxy statement Nov 2, 2010 Nov 2, 2010
DEF 14A Proxy statement May 28, 2010 Jun 30, 2010
PRE 14A Preliminary proxy statement May 19, 2010 May 19, 2010
DEFA14A Additional proxy material May 8, 2009 —
DEF 14A Proxy statement Apr 7, 2009 May 28, 2009
PRE 14A Preliminary proxy statement Mar 25, 2009 May 28, 2009
DEF 14A Proxy statement Oct 30, 2008 Dec 9, 2008
PRE 14A Preliminary proxy statement Oct 10, 2008 Oct 10, 2008
DEF 14A Proxy statement Apr 28, 2008 Jul 23, 2008
PRE 14A Preliminary proxy statement Apr 18, 2008 Jul 23, 2008
DEF 14A Proxy statement Apr 27, 2007 Jun 13, 2007
DEF 14A Proxy statement Apr 28, 2006 Jun 14, 2006

Showing 48 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
OTLC (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Aguora Hills, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
908259
Former names
MATEON THERAPEUTICS INC (until Mar 26, 2021); OXIGENE INC (until Jun 3, 2016)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.